Voya Investment Management LLC Buys 18,812 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Voya Investment Management LLC grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 56.3% in the third quarter, Holdings Channel reports. The fund owned 52,213 shares of the company’s stock after acquiring an additional 18,812 shares during the quarter. Voya Investment Management LLC’s holdings in Harmony Biosciences were worth $1,439,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. grew its position in Harmony Biosciences by 288.2% during the 1st quarter. Raymond James Financial Inc. now owns 147,164 shares of the company’s stock worth $4,884,000 after acquiring an additional 109,257 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Harmony Biosciences during the first quarter valued at about $543,000. Hsbc Holdings PLC grew its holdings in shares of Harmony Biosciences by 6.9% during the first quarter. Hsbc Holdings PLC now owns 21,803 shares of the company’s stock worth $714,000 after purchasing an additional 1,402 shares during the last quarter. Comerica Bank increased its stake in shares of Harmony Biosciences by 6.3% in the first quarter. Comerica Bank now owns 14,342 shares of the company’s stock valued at $476,000 after buying an additional 847 shares during the period. Finally, Ieq Capital LLC bought a new position in Harmony Biosciences in the 1st quarter valued at approximately $202,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Activity at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 23.60% of the stock is currently owned by company insiders.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock opened at $37.91 on Tuesday. The business has a 50-day moving average price of $34.62 and a two-hundred day moving average price of $33.54. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $40.93. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. The company has a market cap of $2.18 billion, a P/E ratio of 11.92, a PEG ratio of 0.48 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The business had revenue of $239.46 million for the quarter, compared to the consensus estimate of $222.68 million. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on HRMY shares. Wall Street Zen upgraded shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Mizuho boosted their price objective on shares of Harmony Biosciences from $39.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, December 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price target on shares of Harmony Biosciences in a research report on Monday, November 24th. Finally, HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.63.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.